Fulcrum Therapeutics Inc (FULC) Stock Price, Quote & News

Company Profile

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Fa...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 651 8851

Website: www.fulcrumtx.com

Address:

26 Landsdowne Street, Cambridge, United States

zerodayrounder Apr. 15 at 7:36 PM

$SPRO just went back and looked -- Esther is not a public company biotech CEO imo -- she spent ~20 years covering biotech as sell-side analyst. Hired as $FULC CFO in January 2022 --- FULC founder came back in January 2023, then FULC raised $125 million few weeks later, then their sickle cell drug candidate got bad news in Feb 2023 and the stock got crushed -- Esther resigns from FULC in April 2023 (pushed out by founder/Board?). Hired as SPRO CFO in November 2023 -- takes interim then permanent title after Ankit/Shay have their problems in 2024/2025. Esther is a care-taker CEO --- if anything happens with "SPRO 2.0" and selling tebi and reorienting SPRO into a growth biotech again -- it will be with a new CEO running the show. I'm pretty certain of that.

2 · Reply

SuperGreenToday Mar. 23 at 9:11 PM

$FULC Share Price: $6.89 Contract Selected: Jan 15, 2027 $5 Calls Buy Zone: $1.36 – $1.68 Target Zone: $2.55 – $3.12 Potential Upside: 77% ROI Time to Expiration: 297 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BKronic5 Mar. 23 at 2:41 PM

$FULC 16.47 down to 6.09. Why can’t this thing just push once and for all

0 · Reply

Merlintrader Mar. 19 at 2:43 PM

$FULC https://www.merlintrader.com/fulcrum-therapeutics-inc-dd-march19/

0 · Reply

DARKP00L Mar. 19 at 12:30 PM

$FULC 08:26 on Mar. 19 2026 MedicAlert Foundation, SCDAA And Fulcrum Therapeutics Partner To Help Streamline And Expedite ED Care For People Living With Sickle Cell Disease Through Rapid Access To Patient-Specific Care Plans #tradeideas

0 · Reply

Yi_YandH Mar. 15 at 8:34 PM

$FULC &. $ICU

0 · Reply

elmono Mar. 2 at 3:29 PM

$FULC junk

0 · Reply

Jack_Nicholson_Truth Feb. 25 at 3:16 PM

$FULC let's go back to 11 after that dumb drop. If 20%, fulc would be $25 now. 19.4% is $8.50 with $5 in cash. 100% premium to buy fulc now would be $18 or $1.2B to get the most advanced oral pill for sickle cell. Shake out retail first. Then climb to where the offering was at $13.50 as fda meeting minutes come out. The ceo wants to cash out and not do P3 imho

1 · Reply

Jack_Nicholson_Truth Feb. 24 at 8:17 PM

$FULC OK I bought more. Active oral drug with 380m cash and 580m market cap now. CEO wants to sell and partner. If you can wait a few days we might have another ocul situation where the dip is bought up. Fulc only at 3.5m volume and lots of funds involved. Risk vs reward

0 · Reply

Spenny777 Feb. 24 at 7:47 PM

$FULC bought more at 8.87, thanks! Let's

0 · Reply

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET

Mar 19, 2026, 8:00 AM EDT - 5 weeks ago

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

Mar 10, 2026, 1:00 PM EDT - 6 weeks ago

Fulcrum Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 6, 2026, 4:30 PM EST - 7 weeks ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2026, 8:30 AM EST - 7 weeks ago

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Feb 24, 2026, 8:00 AM EST - 2 months ago

Fulcrum Therapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 7:01 AM EST - 2 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

Feb 24, 2026, 7:00 AM EST - 2 months ago

Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Feb 17, 2026, 8:00 AM EST - 2 months ago

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jan 14, 2026, 10:30 AM EST - 3 months ago

Fulcrum Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:00 AM EST - 3 months ago

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 10, 2025, 7:48 AM EST - 4 months ago

Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 4 months ago

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

Dec 8, 2025, 1:06 PM EST - 4 months ago

Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results

Dec 7, 2025, 7:00 AM EST - 4 months ago

Fulcrum Therapeutics Transcript: Status Update

Dec 6, 2025, 5:30 PM EST - 5 months ago

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Dec 2, 2025, 8:30 AM EST - 5 months ago

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

Nov 3, 2025, 4:45 PM EST - 6 months ago

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Oct 29, 2025, 8:00 AM EDT - 6 months ago

Fulcrum Therapeutics Earnings Call Transcript: Q3 2025

Oct 29, 2025, 7:00 AM EDT - 6 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

Oct 22, 2025, 8:54 AM EDT - 6 months ago

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

Sep 9, 2025, 2:00 PM EDT - 8 months ago

Fulcrum Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 1:35 PM EDT - 8 months ago

Fulcrum Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 26, 2025, 8:00 AM EDT - 8 months ago

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

Jul 29, 2025, 6:48 AM EDT - 9 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

Jul 29, 2025, 6:45 AM EDT - 9 months ago

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jul 28, 2025, 4:01 PM EDT - 9 months ago

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jun 11, 2025, 8:00 AM EDT - 11 months ago

Fulcrum Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025, 4:10 PM EDT - 11 months ago

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

May 29, 2025, 8:30 AM EDT - 11 months ago

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 21, 2025, 3:35 PM EDT - 1 year ago

Fulcrum Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Fulcrum Therapeutics to Participate in Upcoming May Conferences

May 1, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Earnings Call Transcript: Q1 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

Mar 11, 2025, 8:40 AM EDT - 1 year ago

Fulcrum Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Feb 25, 2025, 8:00 AM EST - 1 year ago

Fulcrum Therapeutics Earnings Call Transcript: Q4 2024

Feb 25, 2025, 7:00 AM EST - 1 year ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

Feb 18, 2025, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

Feb 12, 2025, 1:20 PM EST - 1 year ago

Fulcrum Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 6, 2025, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dec 3, 2024, 12:00 PM EST - 1 year ago

Fulcrum Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Nov 19, 2024, 3:35 PM EST - 1 year ago

Fulcrum Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 1 year ago

Fulcrum Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 8:00 AM EST - 1 year ago

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

Oct 7, 2024, 2:03 PM EDT - 1 year ago

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

Oct 2, 2024, 6:30 PM EDT - 1 year ago

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Oct 1, 2024, 6:15 PM EDT - 1 year ago

Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation

Sep 30, 2024, 8:00 PM EDT - 1 year ago

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Sep 28, 2024, 8:00 PM EDT - 1 year ago

The Schall Law Firm Is Looking Into Whether Fulcrum Therapeutics Inc Committed Securities Fraud And Impacted Investors Should Reach Out

Sep 27, 2024, 6:30 PM EDT - 1 year ago

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Fulcrum Therapeutics, Inc. For Violating Securities Laws

Sep 27, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Fulcrum Therapeutics Earnings Call Transcript: Q2 2024

Jun 10, 2024, 10:00 AM EDT - 2 years ago

Fulcrum Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 20, 2024, 11:30 AM EDT - 2 years ago

Fulcrum Therapeutics Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 15, 2024, 4:05 PM EDT - 2 years ago

Fulcrum Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 13, 2024, 8:00 AM EDT - 2 years ago

Fulcrum Therapeutics Earnings Call Transcript: Q1 2024

Apr 2, 2024, 10:40 AM EDT - 2 years ago

Fulcrum Therapeutics Transcript: Cantor Fitzgerald’s Virtual Muscular Dystrophy Symposium 2024

Mar 13, 2024, 9:20 AM EDT - 2 years ago

Fulcrum Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Feb 27, 2024, 8:00 AM EST - 2 years ago

Fulcrum Therapeutics Earnings Call Transcript: Q4 2023

Feb 13, 2024, 1:20 PM EST - 2 years ago

Fulcrum Therapeutics Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Nov 30, 2023, 11:00 AM EST - 2 years ago

Fulcrum Therapeutics Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 7, 2023, 8:00 AM EST - 2 years ago

Fulcrum Therapeutics Earnings Call Transcript: Q3 2023

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Fulcrum Therapeutics Earnings Call Transcript: Q2 2023

May 15, 2023, 8:00 AM EDT - 3 years ago

Fulcrum Therapeutics Earnings Call Transcript: Q1 2023

Mar 9, 2023, 8:00 AM EST - 3 years ago

Fulcrum Therapeutics Earnings Call Transcript: Q4 2022

Jan 11, 2023, 7:30 PM EST - 3 years ago

Fulcrum Therapeutics Transcript: JPMorgan Healthcare Conference

Nov 8, 2022, 8:00 AM EST - 3 years ago

Fulcrum Therapeutics Earnings Call Transcript: Q3 2022

zerodayrounder Apr. 15 at 7:36 PM

2 · Reply

SuperGreenToday Mar. 23 at 9:11 PM

0 · Reply

BKronic5 Mar. 23 at 2:41 PM

$FULC 16.47 down to 6.09. Why can’t this thing just push once and for all

0 · Reply

Merlintrader Mar. 19 at 2:43 PM

$FULC https://www.merlintrader.com/fulcrum-therapeutics-inc-dd-march19/

0 · Reply

DARKP00L Mar. 19 at 12:30 PM

0 · Reply

Yi_YandH Mar. 15 at 8:34 PM

$FULC &. $ICU

0 · Reply

elmono Mar. 2 at 3:29 PM

$FULC junk

0 · Reply

Jack_Nicholson_Truth Feb. 25 at 3:16 PM

1 · Reply

Jack_Nicholson_Truth Feb. 24 at 8:17 PM

0 · Reply

Spenny777 Feb. 24 at 7:47 PM

$FULC bought more at 8.87, thanks! Let's

0 · Reply

d_risk Feb. 24 at 6:00 PM

$FULC - Fulcrum Therapeutics Inc - 10K - Updated Risk Factors FULC’s risk profile now emphasizes ongoing development and early Phase 1b experience with pociredir in SCD, new tax uncertainty from the 2025 One Big Beautiful Bill Act and a deemed Section 382 ownership change, added exposure to evolving global privacy/biometric and data-transfer laws, heightened AI-related cybersecurity and compliance risks, IRA/MFN-style drug pricing pressure, FDA staffing and policy instability, and the end of its MyoKardia collaboration, while legacy losmapimod/FSHD and CAMP4 risks recede. #Biopharmaceuticals #DrugDevelopment #RegulatoryRisk #DataPrivacy #DrugPricingPressure 🟢 Added 🟠 Removed https://d-risk.ai/FULC/10-K/2026-02-24

0 · Reply

Quantumup Feb. 24 at 4:29 PM

Stifel reiterated $FULC Buy/$25 and said it thinks the Market is Splitting Hairs & Misses the Bigger Picture. $CRPR - VRTX $NVO $AGIO $BEAM Oppenheimer reiterated FULC Outperform; $15 PT, and said, We Think FULC Shares are Trading Down Today Because of Profit-Taking. Here's what else Stifel and Oppenheimer had to say: https://x.com/Quantumup1/status/2026332962359263672?s=20

0 · Reply

Jack_Nicholson_Truth Feb. 24 at 3:33 PM

$FULC bought more at 8.90 thank you.

0 · Reply

elmono Feb. 24 at 3:28 PM

$FULC algos driving it in the ground….I can see the SL picking in front of me. Too bad

1 · Reply

Jack_Nicholson_Truth Feb. 24 at 2:53 PM

$FULC thank you for the 1000 shares at 9.5. I thank you if you didn't even enter the 8k into chatgpt and ask it if the data was good.

1 · Reply

OpenOutcrier Feb. 24 at 2:03 PM

$FULC (-12.8% pre) Form S-8 Fulcrum Therapeutics (2/2) - SI https://ooc.bz/l/94443

0 · Reply

OpenOutcrier Feb. 24 at 2:03 PM

$FULC (-12.8% pre) Fulcrum Therapeutics reports positive trial results for sickle cell drug (1/2) - SI https://ooc.bz/l/94441

0 · Reply

StocktwitsEarnings Feb. 24 at 1:33 PM

$FULC Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.31 • Fulcrum Therapeutics expects to fund operations into 2029 with $352.3M in cash, cash equivalents, and marketable securities as of December 31, 2025, and plans to initiate a potential registration-enabling trial for pociredir in SCD in the second half of 2026.

0 · Reply

DARKP00L Feb. 24 at 1:01 PM

$FULC 07:19 on Feb. 24 2026 Fulcrum Therapeutics Reports 12-Week Results From 20 Mg Dose Cohort Of Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease #tradeideas

0 · Reply

CH_Expat Feb. 24 at 12:55 PM

$FULC Data looks very solid. Would not wonder if this is just pre market fuckery.

0 · Reply

SannieVerraderlijk Feb. 24 at 12:37 PM

$FULC Shitty reaction on ok data, will hold a couple of months

0 · Reply

elmono Feb. 24 at 12:25 PM

$FULC fuck FULC 😂😂😂😂👇💩

0 · Reply

Market Cap	522.14M
Revenue (ttm)	0.00
Net Income (ttm)	-74.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	839,200
Avg Vol	1,156,014
Day's Range	N/A - N/A
Shares Out	66.60M
Stochastic %K	40%
Beta	3.27
Analysts	Strong Sell
Price Target	$19.00